Christine Zedelmayer Sells 11,900 Shares of Equillium (NASDAQ:EQ) Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 11,900 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $1.31, for a total value of $15,589.00. Following the sale, the chief operating officer owned 91,444 shares of the company’s stock, valued at approximately $119,791.64. The trade was a 11.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Christine Zedelmayer also recently made the following trade(s):

• On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The stock was sold at an average price of $1.34, for a total value of $31,897.36.
• On Tuesday, November 25th, Christine Zedelmayer sold 8,098 shares of Equillium stock. The shares were sold at an average price of $0.95, for a total transaction of $7,693.10.

Equillium Stock Performance

EQ stock traded down $0.06 during midday trading on Monday, hitting $1.22. 469,524 shares of the company’s stock were exchanged, compared to its average volume of 2,628,076. The stock’s fifty day moving average price is $1.17 and its 200-day moving average price is $0.99. Equillium, Inc. has a one year low of $0.27 and a one year high of $2.35. The company has a market cap of $74.29 million, a PE ratio of -1.97 and a beta of 1.93.

Equillium (NASDAQ:EQ) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.08. On average, analysts expect that Equillium, Inc. will post 0.14 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC grew its stake in shares of Equillium by 133.4% in the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock worth $34,000 after acquiring an additional 13,591 shares in the last quarter. Millennium Management LLC bought a new stake in Equillium in the 3rd quarter worth about $35,000. Persistent Asset Partners Ltd purchased a new stake in Equillium in the 3rd quarter valued at about $99,000. Boothbay Fund Management LLC bought a new position in shares of Equillium during the 3rd quarter worth approximately $174,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Equillium during the 3rd quarter worth approximately $178,000. 27.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

EQ has been the topic of several recent research reports. Wall Street Zen raised shares of Equillium from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a research report on Monday, December 8th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Equillium presently has an average rating of “Reduce” and a consensus target price of $1.00.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.